



A TEC Perspective

Diabetes Mellitus and Ca
13 April, 2011

Mark Grant, MD, MPH
Director, TEC Assessments, Tec
Blue Cross Blue Shield Association



TEC Criteria

1. The technology must have final approval from governmental regulatory bodies.
2. The scientific evidence must permit conclusive effect of the technology on health outcomes.
3. The technology must improve the net health
4. The technology must be as beneficial as any alternatives.
5. The improvement must be attainable outside settings

Rosiglitazone 2007

	Event Rates ^a	
	Control	Rosiglitazone
MI	0.46%	0.55%
Cardiac Death	0.24%	0.28%
MI		
	Relative Odds	
Published	1.43 (1.03 to 1.98)	
Me	1.48 (1.01 to 2.16)	
Me Predictive	1.64 (0.73 to 3.13)	
Monotherapy		
	Difference in Expected ^b	
Cohort Mean Age 57	Life-Years	QALYs
Metformin	—	—
Rosiglitazone	0.026	0.009

